GrittGene Therapeutics is working closely with leading physicians and top global experts in neuromuscular and rare diseases to better understand Myotonic Dystrophy Type 2 (DM2) and to advance new therapeutic approaches for this condition.
We are currently:
Conducting a DM2 natural history multi-omics study to better understand how the disease progresses over time
Working on the development of a therapeutic program for DM2
Collaborating with international experts, clinicians, and researchers, because progress starts with deep scientific and clinical understanding
Partnering directly with patients, whose lived experiences are at the heart of our work
If you are a DM2 patient and are interested in learning more or participating in research efforts, we invite you to reach out.